CNBX Pharmaceuticals (CNBX Pharmaceuticals) Debt-to-Equity : -0.55 (As of Feb. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Debt-to-Equity?

CNBX Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $1.29 Mil. CNBX Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.00 Mil. CNBX Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $-2.36 Mil. CNBX Pharmaceuticals's debt to equity for the quarter that ended in Feb. 2024 was -0.55.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CNBX Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

CNBX' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.05 Med: -0.63 Max: 1.71
Current: -0.55

During the past 13 years, the highest Debt-to-Equity Ratio of CNBX Pharmaceuticals was 1.71. The lowest was -2.05. And the median was -0.63.

CNBX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs CNBX: -0.55

CNBX Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for CNBX Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Debt-to-Equity Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Debt-to-Equity

Get a 7-Day Free Trial

0.48

-1.08

-0.67

CNBX Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															-0.77	-0.70	-0.67	-0.63	-0.55

Competitive Comparison of CNBX Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, CNBX Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNBX Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Debt-to-Equity falls into.

CNBX Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CNBX Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.344	+	0)	/	-2.017
	=	-0.67

CNBX Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.293	+	0)	/	-2.359
	=	-0.55

CNBX Pharmaceuticals (OTCPK:CNBX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CNBX Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary